Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

Author(s): Daniele Rossini, MD^1,2;Carlotta Antoniotti, MD, PhD^1,2;Sara Lonardi, MD³;Filippo Pietrantonio, MD⁴;Roberto Moretto, MD²;Lorenzo Antonuzzo, MD, PhD⁵;Alessandra Boccaccino, MD^1,2;Federica Morano, MD⁴;Marco Brugia, MD⁶;Carmelo Pozzo, MD⁷;Federica Marmorino, MD, PhD^1,2;Francesca Bergamo, MD⁸;Emiliano Tamburini, MD⁹;Alessandro Passardi, MD¹⁰;Giovanni Randon, MD⁴;Sabina Murgioni, MD⁸;Beatrice Borelli, MD^1,2;Angela Buonadonna, MD¹¹;Mirella Giordano, PhD^1,2;Gabriella Fontanini, MD, PhD¹²;Veronica Conca, MD^1,2;Vincenzo Formica, MD, PhD¹³;Massimo Aglietta, MD¹⁴;Roberto Bordonaro, MD¹⁵;Giuseppe Aprile, MD¹⁶;Gianluca Masi, MD^1,2;Luca Boni, MD¹⁷;and Chiara Cremolini, MD, PhD^1,2

Source: DOI: 10.1200/JCO.22.00839

Interesting lack of deepened response with chemotherapy intensification. Expected increase in GI toxicity, increased cost and diminished options upon progression place this truly a quadruple combination on the shelf.

To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and oxaliplatin when both regimens are combined with panitumumab as initial treatment for RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC).

METHODS

TRIPLETE was a prospective, open-label, phase III trial in which previously untreated patients with unresectable RAS and BRAF wt mCRC were randomly assigned 1:1 to modified FOLFOX/panitumumab (control group) or mFOLFOXIRI/panitumumab (experimental group) up to 12 cycles, followed by fluorouracil/-leucovorin/panitumumab until disease progression. The primary end point was objective response rate (ORR) according to RECIST 1.1. Hypothesizing an ORR of 60% in the control group, 432 cases provided 90% power to a two-sided chi-square test for heterogeneity with a two-sided alpha error of .05 to detect ≥ 15% differences between arms (ClinicalTrials.gov identifier: NCT03231722).

RESULTS

From September 2017 to September 2021, 435 patients were enrolled (control group/experimental group: 217/218) in 57 Italian sites. One hundred sixty (73%) patients treated with mFOLFOXIRI plus panitumumab and 165 (76%) patients treated with modified FOLFOX plus panitumumab achieved RECIST response (odds ratio 0.87, 95% CI, 0.56 to 1.34, P = .526). No differences in early tumor shrinkage rate (57%/58%, P = .878) and deepness of response (median: 48%/47%, P = .845) were reported, nor in R0 resection rate (25%/29%, P = .317). No significant difference between arms was reported in terms of progression-free survival (median progression-free survival: 12.7 in the experimental group v 12.3 months in the control group, hazard ratio: 0.88, 95% CI, 0.70 to 1.11, P = .277).

CONCLUSION

The intensification of the upfront chemotherapy backbone in combination with panitumumab does not provide additional benefit in terms of treatment activity at the price of increased gastrointestinal toxicity in patients with RAS and BRAF wt mCRC.

Author Affiliations

¹Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy²Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy³Medical Oncology 3, Veneto Institute of Oncology IOV—IRCCS, Padua, Italy⁴Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy⁵Clinical Oncology Unit, Careggi University Hospital—Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy⁶Medical Oncology Unit, Careggi University Hospital, Florence, Italy⁷Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy⁸Medical Oncology 1, Veneto Institute of Oncology IOV—IRCCS, Padua, Italy⁹Oncology and Palliative Care Department, Cardinale G. Panico Tricase City Hospital, Tricase, Italy¹⁰Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy¹¹Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy¹²Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy¹³Medical Oncology Unit, Tor Vergata University Hospital, Rome, Italy¹⁴Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Torino, Italy¹⁵Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e Alta Specializzazione (ARNAS), Ospedale Garibaldi, Catania, Italy¹⁶Department of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy¹⁷Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Here is a large phase-III well done study confirming what we knew from earlier studies, that ipilimumab plus nivolumab (Ipi+Nivo) is highly active and effective in the microsatellite instability-high metastatic colorectal cancer (MSI-high met-CRC) population. This is most likely more effective than single agent IO therapy but with higher rates of toxicity. When all things are equal, I would consider this to be the standard of care (SOC) in this context.

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

This Japanese study showed no benefit with the addition of oxaliplatin to fluoropyrimidine plus bevacizumab (5FU+bev) in patients who were aged 70-74 but unfit, or >=75. Interestingly survival was actually shorter in the patients who received oxaliplatin at 21.3 vs 19.7 months.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Overall survival (OS) improvement was not statistically significant in the study arm but is a non-chemotherapy option. Patients here had tumors with MSS.

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

Less maintenance is NOT NON-inferior, so it is inferior in patients with wild type BRAF metastatic colon cancer. So it is better to keep on the full regimen. Although, quality of life is better.

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

Colorectal cancer screening by peripheral blood testing? This cell-free DNA assay had an 83% sensitivity and 90% specificity for advanced neoplasia. However, the issue is that this does not detect precancerous lesions well. Colonoscopy has its obvious advantages as it can both diagnose colorectal cancer as well as eradicate precancerous lesions.